FY2026 EPS Estimates for AGIO Increased by Cantor Fitzgerald

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Analysts at Cantor Fitzgerald increased their FY2026 earnings per share estimates for Agios Pharmaceuticals in a research note issued on Tuesday, November 25th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the biopharmaceutical company will post earnings of ($5.37) per share for the year, up from their prior estimate of ($7.26). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.15. The company had revenue of $12.90 million for the quarter, compared to the consensus estimate of $10.49 million. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The company’s quarterly revenue was up 43.3% compared to the same quarter last year. During the same period last year, the business posted $16.22 EPS.

A number of other brokerages have also recently weighed in on AGIO. JPMorgan Chase & Co. reduced their price target on shares of Agios Pharmaceuticals from $37.00 to $20.00 and set a “neutral” rating on the stock in a research report on Friday, November 21st. Royal Bank Of Canada downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their target price for the company from $57.00 to $28.00 in a research note on Wednesday, November 19th. HC Wainwright reduced their target price on shares of Agios Pharmaceuticals from $56.00 to $48.00 and set a “buy” rating on the stock in a report on Thursday, November 20th. Leerink Partners raised Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and cut their price objective for the company from $40.00 to $34.00 in a research report on Thursday, November 20th. Finally, Zacks Research upgraded Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.78.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ:AGIO opened at $29.04 on Thursday. The stock has a 50-day simple moving average of $39.40 and a 200-day simple moving average of $36.85. The stock has a market capitalization of $1.69 billion, a P/E ratio of -4.15 and a beta of 0.89. Agios Pharmaceuticals has a 1 year low of $22.24 and a 1 year high of $62.45.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 3,302 shares of the business’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $43.92, for a total value of $145,023.84. Following the transaction, the insider owned 61,727 shares in the company, valued at $2,711,049.84. The trade was a 5.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Cecilia Jones sold 3,651 shares of the company’s stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $36.77, for a total transaction of $134,247.27. Following the completion of the transaction, the chief financial officer directly owned 33,870 shares of the company’s stock, valued at approximately $1,245,399.90. The trade was a 9.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 16,099 shares of company stock valued at $620,092 in the last quarter. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Agios Pharmaceuticals by 30.7% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 505,225 shares of the biopharmaceutical company’s stock worth $16,804,000 after buying an additional 118,702 shares during the last quarter. Savvy Advisors Inc. bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at approximately $724,000. Strs Ohio acquired a new stake in shares of Agios Pharmaceuticals during the 1st quarter valued at approximately $240,000. American Century Companies Inc. lifted its stake in Agios Pharmaceuticals by 9.6% during the first quarter. American Century Companies Inc. now owns 114,947 shares of the biopharmaceutical company’s stock worth $3,368,000 after purchasing an additional 10,110 shares during the last quarter. Finally, Nordea Investment Management AB boosted its holdings in Agios Pharmaceuticals by 0.3% in the second quarter. Nordea Investment Management AB now owns 224,746 shares of the biopharmaceutical company’s stock worth $7,520,000 after purchasing an additional 573 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.